The energy sensor AMPK regulates Hedgehog signaling in human cells through a unique Gli1 metabolic checkpoint
Metrics: PDF 1612 views | HTML 1396 views | ?
Laura Di Magno3, Alessio Basile1, Sonia Coni1, Simona Manni1, Giulia Sdruscia3, Davide D’Amico1, Laura Antonucci1, Paola Infante3, Enrico De Smaele2, Danilo Cucchi2, Elisabetta Ferretti2, Lucia Di Marcotullio1,3,4, Isabella Screpanti1,3,4, Gianluca Canettieri1,4
1Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy
2Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy
3Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, 00161 Roma, Italy
4Istituto Pasteur, Fondazione Cenci-Bolognetti, Sapienza University of Rome, 00161 Rome, Italy
Gianluca Canettieri, e-mail: email@example.com
Keywords: Hedgehog, AMPK, Gli1, cancer metabolism, phosphorylation
Received: August 18, 2015 Accepted: January 12, 2016 Published: January 29, 2016
Hedgehog signaling controls proliferation of cerebellar granule cell precursors (GCPs) and its aberrant activation is a leading cause of Medulloblastoma, the most frequent pediatric brain tumor. We show here that the energy sensor AMPK inhibits Hh signaling by phosphorylating a single residue of human Gli1 that is not conserved in other species.
Studies with selective agonists and genetic deletion have revealed that AMPK activation inhibits canonical Hh signaling in human, but not in mouse cells. Indeed we show that AMPK phosphorylates Gli1 at the unique residue Ser408, which is conserved only in primates but not in other species. Once phosphorylated, Gli1 is targeted for proteasomal degradation. Notably, we show that selective AMPK activation inhibits Gli1-driven proliferation and that this effect is linked to Ser408 phosphorylation, which represents a key metabolic checkpoint for Hh signaling.
Collectively, this data unveil a novel mechanism of inhibition of Gli1 function, which is exclusive for human cells and may be exploited for the treatment of Medulloblastoma or other Gli1 driven tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.